The Use of SMS 201-995 (Somatostatin Analogue) in Insulinomas

Hearn, P. R.; Ahmed, Manzur; Woodhouse, Nicholas

doi:10.1159/000181005

Cited by 16 publications

(7 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The effective dose was unrelated to body mass index, age, serum creatinine or insulinoma size and had to be adapted to each patient's blood glucose levels. There are reports of insulinoma patients who need only 25 or 50 µg/day octreotide to normalize blood glucose levels 12,25,26 . Similarly to what has been reported previously in acromegaly, we did not observe tachyphylaxis in our patients on long‐term treatment 27 .…”

Section: Discussionsupporting

confidence: 89%

Short‐ and long‐term somatostatin analogue treatment in patients with hypoglycaemia related to endogenous hyperinsulinism

Vezzosi¹,

Bennet²,

Courbon

et al. 2007

Clinical Endocrinology

View full text Add to dashboard Cite

Summary Background The long‐term efficacy of somatostatin analogues on insulinomas has not been studied. Design A prospective study to evaluate the response of octreotide in 21 patients with hypoglycaemia related to endogenous hyperinsulinism who were not treated by surgery. Results Reasons for not undergoing surgery were: refusal (n = 3), old age with multiple diseases (n = 5), unlocalized insulinomas (n = 2), malignant unresectable insulinomas (n = 5), multiple insulinomas (n = 3) and diffuse β‐cell disease (n = 3). Hypoglycaemia was responsive to octreotide in 14 of the 21 patients. A short 100‐µg octreotide test correctly predicted the efficacy of treatment in six patients with benign insulinomas. Octreoscan scintigraphy was positive in 6 of the 16 patients of whom three were responsive and three unresponsive to octreotide. Octreoscan scintigraphy was negative in 10 of the 16 patients, eight of whom were responsive to octreotide. Subcutaneous octreotide treatment was prolonged for > 6 months (7–144 months, 67 ± 47 months) in 11 responsive patients. No tachyphylaxis was observed. However, the octreotide dose had to be increased in two patients after 3 and 18 months, respectively. Only one patient suffered from symptomatic biliary lithiasis after 3 years of treatment. Conclusion Long‐term octreotide treatment can be used to control hypoglycaemia in patients with endogenous hyperinsulinism who are not eligible for surgery; octreotide efficacy on hypoglycaemia could be predicted by a short 100 µg‐octreotide test in patients with benign insulinomas, but was not correctly predicted by Octreoscan scintigraphy.

show abstract

Section: Discussionsupporting

confidence: 89%

Short‐ and long‐term somatostatin analogue treatment in patients with hypoglycaemia related to endogenous hyperinsulinism

Vezzosi¹,

Bennet²,

Courbon

et al. 2007

Clinical Endocrinology

View full text Add to dashboard Cite

show abstract

“…The treatment was effective in all SSTR 2 positive patients and in a few SSTR 2 negative ones, while no relation between treatment effectiveness and the expression of SSTR 5 was observed (40). These results are in concordance with other case reports and smaller series of insulinoma patients reported in the literature (41–45). In glucagonoma patients SST analog treatment is indicated to reduce the symptoms related to the characteristic skin rash (necrolytic migratory erythema) or diarrhea (46–50).…”

Section: The Symptomatic and Biochemical Effects Of Sst Analogssupporting

confidence: 93%

Somatostatin Analogs Therapy in Gastroenteropancreatic Neuroendocrine Tumors: Current Aspects and New Perspectives

Baldelli¹,

Barnabei²,

Rizzà

et al. 2014

Front. Endocrinol.

View full text Add to dashboard Cite

Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare tumors that present many clinical features secreting peptides and neuroamines that cause distinct clinical syndromes such as carcinoid syndrome. However most of them are clinically silent until late presentation with mass effects. Surgical resection is the first line treatment for a patient with a GEP-NET while in metastatic disease multiple therapeutic approaches are possible. GEP-NETs are able to express somatostatin receptors (SSTRs) bounded by somatostatin (SST) or its synthetic analogs, although the subtypes and number of SSTRs expressed are very variable. In particular, SST analogs are used frequently to control hormone-related symptoms while their anti-neoplastic activity seems to result prevalently in tumor stabilization. Patients who fail to respond or cease to respond to standard SST analogs treatment seem to have a response to higher doses of these drugs. For this reason, the use of higher doses of SST analogs will probably improve the clinical management of these patients.

show abstract

“…Recently, in patients with acromegaly, the availability of the long-acting octreotide formulation, octreotide LAR, has improved patients' compliance to long-term treatment [8]. In several reports of insulinoma, octreotide was used for the control of hypoglycemia and body weight prior to surgery [1,3], or because of failure to localize the tumor [1,[4][5][6]. Octreotide has also been used to control hypoglycemia in cases of malignant insulinoma [1].…”

Section: Of Somatostatin Receptors (Octreoscan)mentioning

confidence: 99%

“…The somatostatin analogue, octreotide, is known to suppress the secretion of insulin in healthy subjects as well as in some patients with insulinoma. Several studies have reported the usefulness of octreotide in patients with benign and malignant insulinomas [1][2][3][4][5][6][7]. However, as octreotide is a shortacting formulation, several subcutaneous injections per day are required for effective treatment.…”

mentioning

confidence: 99%

Medical Treatment of Benign Insulinoma Using Octreotide LAR: A Case Report

et al. 2007

View full text Add to dashboard Cite

Abstract. In some patients with insulinoma, surgery is not possible due to either difficulties in detecting the tumor or advanced age. These patients need medical treatment for hypoglycemia. We report a case of benign insulinoma using the long-acting octreotide formulation, octreotide long-acting repeatable (octreotide LAR), as a medical therapy. A 67-yearold woman was referred to our hospital for examinations of hypoglycemia. A blood sample taken during a hypoglycemic episode revealed low plasma glucose concentration, hyperinsulinemia and a high C-peptide level. An abdominal CT scan demonstrated a hypervascular tumor in the body of pancreas. She was diagnosed with insulinoma. As the patient refused surgical resection of the pancreas tumor, we started to use the somatostatin analogue, octreotide, for treatment of hypoglycemia. After the treatment her plasma glucose levels were elevated and serum immunoreactive insulin (IRI) levels were decreased. For long-term treatment, we changed the treatment from daily subcutaneous injection of octreotide to monthly intramuscular administration of octreotide LAR. This treatment was also effective and hypoglycemic attacks disappeared. Both plasma glucose levels and serum IRI levels were improved. Our case demonstrated that octreotide LAR was useful for long-term medical treatment of insulinoma.

show abstract

The Use of SMS 201-995 (Somatostatin Analogue) in Insulinomas

Cited by 16 publications

References 12 publications

Short‐ and long‐term somatostatin analogue treatment in patients with hypoglycaemia related to endogenous hyperinsulinism

Short‐ and long‐term somatostatin analogue treatment in patients with hypoglycaemia related to endogenous hyperinsulinism

Somatostatin Analogs Therapy in Gastroenteropancreatic Neuroendocrine Tumors: Current Aspects and New Perspectives

Medical Treatment of Benign Insulinoma Using Octreotide LAR: A Case Report

Contact Info

Product

Resources

About